Online inquiry

IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9599MR)

This product GTTS-WQ9599MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets VSIR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_022153.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 64115
UniProt ID Q9H7M9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ9599MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13558MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ6304MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ2382MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ4343MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ7105MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ7676MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ10868MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ14981MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SHR-1314
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW